查詢結果分析
相關文獻
- 非小細胞肺癌ALK抑制劑簡介
- 非小細胞肺癌術前輔助性化學治療的經驗
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- 非小細胞肺癌的治療
- 晚期非小細胞肺癌之化學治療
- CA405之基因療法合併化學抗癌藥物對肺癌細胞之作用效果評估與機轉的探討(2)
- Treatment of Non-Small-Cell Lung Cancer: The Chinese Experience in a General Teaching Hospital
- erbB基因與非小細胞肺癌的原發抗藥性
- Concurrent 5-Fluorouracil, Leucovorin, Etoposide, Cisplatin and Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
頁籤選單縮合
題名 | 非小細胞肺癌ALK抑制劑簡介=Introduction of ALK Inhibitor in Non-Small Cell Lung Cancer |
---|---|
作者 | 陳弘益; Chen, Hung-yi; |
期刊 | 藥學雜誌 |
出版日期 | 20170300 |
卷期 | 33:1=130 2017.03[民106.03] |
頁次 | 頁89-93 |
分類號 | 418.29 |
語文 | chi |
關鍵詞 | 非小細胞肺癌; 酪胺酸激酶受體抑制劑; ALK; TKI; EML-4; |
中文摘要 | 衛福部國健署於105年4月公布102年癌症發生統計報告,肺癌新增個案有11,751 位,在所有癌症中排名第二,十大癌症死因順位排行第一位,肺癌中約有85%屬於 非小細胞肺癌 (non-small cell lung cancer NSCLC),常在晚期才被診斷出來。NSCLC 病人約有2-7%會有致癌基因 ALK (anaplastic lymphoma kinase, 間變性淋巴瘤激酶) 基因重組,常見與 EML4 (Echinoderm Microtubule Associated Protein Like 4) 基因結 合產生融合基因,促使腫瘤細胞增生及轉移,使用間變性淋巴瘤激酶抑制劑 (ALK inhibitors),可抑制肺癌細胞的增生,目前有三種 NSCLC 的 ALK 抑制劑,第一線用 藥為 crizotinib,第二線用藥為 ceritinib 和 alectinib,本文介紹這些藥品,並說明在藥 品治療 NSCLC 的定位。 |
英文摘要 | In April 2016, health promotion administration, ministry of health and welfare announced cancer statistics of 2013. There were 11,751 new lung cancer cases in Taiwan and ranked second after colorectal cancer. Lung cancer was also the leading cause of mortality of the total malignancies. Non-small cell lung cancer(NSCLC) accounts for 85% of all lung cancer cases and is often found in its advanced stage. Anaplastic lymphoma kinase (ALK) fusion oncogene positive NSCLC account for 2-7% of all advanced NSCLC. The rearrangement on chromosome 2 p, leading to the formation of the EML4-ALK fusion oncogene and stimulate cancer cell proliferation, metastasis and survival. ALK tyrosine kinase inhibitors suppress proliferation of NSCLC. There are three ALK inhibitors in NCCN guideline. Crizotinib is the first line agent for ALK positive NSCLC. Ceritinib and alectinib are the second line agents for NSCLC treatment. These agents will be introduced and discussed in this article. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。